Roohi Mariam Peter

Cardiff

Junior Reporter at Labiotech

Journalist @Labiotech_eu | MA International Journalism @cardiffjomec | she/her

Featured in: Favicon

labiotech.eu Favicon

wetheitalians.com Favicon

hongkongbusinessreporter.com

Articles

Gene therapy for cystic fibrosis gains clinical momentum

2 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*CommentsThis field is for validation purposes and should be left unchanged. For decades, cystic fibrosis has remained a relentless, life-limiting disease. But now, the future of cystic fibrosis care could be shifting from symptom management to something far more revolutionary.
Biotech’s hottest deals of March 2025: key partnerships and M&A you need to know

3 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. The month of March saw biopharmas accelerate drug development in the fields of small molecules, bispecific antibodies, and protein therapeutics, among others.
AstraZeneca's big bet on Asia: $10B in deals amid controversy

3 weeks ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. British pharma giant AstraZeneca, known for its cancer therapies Lynparza and Enhertu, among others, has signed deals on a number of research and development (R&D) projects across the globe.
The 7 hottest biotech companies advancing endometriosis care

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged.
First-ever RIPTAC enters clinic: all you need to know about this new cancer approach

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. You may already be familiar with protein degraders, drugs designed to eliminate disease-causing proteins, which have shown promising activity as cancer therapies.
Why are placebos defeating antidepressants in clinical trials?

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged.
The hottest cancer vaccine companies you should know about

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. A kind of immunotherapy, cancer vaccines have been around since the link between human papillomavirus (HPV) and cancer was discovered in the 1980s.
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells.
23andMe: the collapse of a genomics giant

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. The genetic testing company 23andMe was once synonymous with ancestry mapping and spit parties, but things went sour when reports of DNA data breaches came to light a few years ago.
Top biotech deals of February 2025

1 month ago | labiotech.eu | Roohi Mariam Peter

Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Partnerships are key to accelerating drug development in various therapeutic sectors. In February 2025, several biotech deals worth billions of dollars were inked, and once again, Eli Lilly was a top collaborator.